Grant of Interim Extension of the Term of U.S. Patent No. 5,496,801; Recombinant Human Parathyroid Hormone, 78838 [2013-31017]

Download as PDF 78838 Federal Register / Vol. 78, No. 249 / Friday, December 27, 2013 / Notices Grant of Interim Extension of the Term of U.S. Patent No. 5,496,801; Recombinant Human Parathyroid Hormone regulatory review period has continued beyond the original expiration date of the patent, December 23, 2013, interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 5,496,801 is granted for a period of one year from the original expiration date of the patent. United States Patent and Trademark Office, Commerce. ACTION: Notice of interim patent term extension. Dated: December 20, 2013. Andrew Hirshfeld, Deputy Commissioner for Patent Examination Policy, United States Patent and Trademark Office. DEPARTMENT OF COMMERCE United States Patent and Trademark Office [Docket No.: PTO–P–2013–0062] AGENCY: The United States Patent and Trademark Office has issued an order granting interim extension under 35 U.S.C. 156(d)(5) for a one-year interim extension of the term of U.S. Patent No. 5,496,801. FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 272– 7755; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 22313– 1450; by fax marked to her attention at (571) 273–7755; or by email to Mary.Till@uspto.gov. SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to one year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On December 6, 2013, NPS Pharmaceuticals, Inc., timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of U.S. Patent No. 5,496,801. The patent claims the human biological product recombinant human parathyroid hormone. The application indicates that Biologics License Application 125511 for the drug product, recombinant human parathyroid hormone, was filed on October 24, 2013, and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially. Review of the application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because the tkelley on DSK3SPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 23:48 Dec 26, 2013 Jkt 232001 [FR Doc. 2013–31017 Filed 12–26–13; 8:45 am] BILLING CODE 3510–16–P DEPARTMENT OF COMMERCE United States Patent and Trademark Office [Docket No. PTO–C–2013–0060] National Medal of Technology and Innovation Call for 2014 Nominations United States Patent and Trademark Office, Commerce. ACTION: Notice and request for nominations. AGENCY: The Department of Commerce (United States Patent and Trademark Office) is accepting nominations for the National Medal of Technology and Innovation (NMTI). Since establishment by Congress in the Stevenson-Wydler Technology Innovation Act of 1980, the President of the United States has awarded the annual National Medal of Technology and Innovation (initially known as the National Medal of Technology) to our nation’s leading innovators. If you know of a candidate who has made an outstanding contribution to the nation’s economic, environmental or social well-being through the promotion of technology, technological innovation, or the development of technological manpower, you may obtain a nomination form from: https:// www.uspto.gov/about/nmti/index.jsp. ADDRESSES: The NMTI nomination form for the year 2014 may be obtained by visiting the USPTO Web site at https:// www.uspto.gov/about/nmti/index.jsp. Nomination applications should be submitted to John Palafoutas, Program Manager, National Medal of Technology and Innovation Program, by electronic mail to NMTI@uspto.gov or by mail to: John Palafoutas, NMTI Program Manager, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, Virginia 22313–1450. SUMMARY: PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 The deadline for submission of a nomination is 5 p.m. ET, April 1, 2014. DATES: John Palafoutas, Program Manager, National Medal of Technology and Innovation Program, United States Patent and Trademark Office, 600 Dulany Street, Alexandria, VA 22314; telephone (571) 272–9821 or by electronic mail: nmti@ uspto.gov. FOR FURTHER INFORMATION CONTACT: SUPPLEMENTARY INFORMATION: Background As provided by Congress in the Stevenson-Wydler Technology Innovation Act of 1980, the National Medal of Technology was first awarded in 1985. On August 9, 2007, the President signed the America COMPETES (Creating Opportunities to Meaningfully Promote Excellence in Technology, Education, and Science) Act of 2007. The Act amended Section 16 of the Stevenson-Wydler Technology Innovation Act of 1980, changing the name of the Medal to the ‘‘National Medal of Technology and Innovation.’’ The NMTI is the highest honor awarded by the President of the United States to America’s leading innovators in the field of technology and is given annually to individuals, teams, or companies/non-profits who have made outstanding contributions to the promotion of technology or technological innovation, or to the development of technological manpower, for the improvement of the economic, environmental or social wellbeing of the United States. The primary purpose of the NMTI is to recognize American innovators whose vision, creativity, and brilliance in moving ideas to market or in developing of the nation’s technological manpower has had a profound and significant impact on our economy and way of life. The NMTI highlights the national importance of fostering technological innovation based upon solid science, resulting in commercially successful products and services. Eligibility and Nomination Criteria Nomination Guidelines containing information on eligibility and nomination criteria are at https:// www.uspto.gov/about/nmti/ guidelines.jsp. E:\FR\FM\27DEN1.SGM 27DEN1

Agencies

[Federal Register Volume 78, Number 249 (Friday, December 27, 2013)]
[Notices]
[Page 78838]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-31017]



[[Page 78838]]

-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

[Docket No.: PTO-P-2013-0062]


Grant of Interim Extension of the Term of U.S. Patent No. 
5,496,801; Recombinant Human Parathyroid Hormone

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of interim patent term extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued an 
order granting interim extension under 35 U.S.C. 156(d)(5) for a one-
year interim extension of the term of U.S. Patent No. 5,496,801.

FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 
272-7755; by mail marked to her attention and addressed to the 
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, 
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to one year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On December 6, 2013, NPS Pharmaceuticals, Inc., timely filed an 
application under 35 U.S.C. 156(d)(5) for an interim extension of the 
term of U.S. Patent No. 5,496,801. The patent claims the human 
biological product recombinant human parathyroid hormone. The 
application indicates that Biologics License Application 125511 for the 
drug product, recombinant human parathyroid hormone, was filed on 
October 24, 2013, and is currently undergoing regulatory review before 
the Food and Drug Administration for permission to market or use the 
product commercially.
    Review of the application indicates that, except for permission to 
market or use the product commercially, the subject patent would be 
eligible for an extension of the patent term under 35 U.S.C. 156, and 
that the patent should be extended for one year as required by 35 
U.S.C. 156(d)(5)(B). Because the regulatory review period has continued 
beyond the original expiration date of the patent, December 23, 2013, 
interim extension of the patent term under 35 U.S.C. 156(d)(5) is 
appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 5,496,801 is granted for a period of one year from the 
original expiration date of the patent.

    Dated: December 20, 2013.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination Policy, United States Patent 
and Trademark Office.
[FR Doc. 2013-31017 Filed 12-26-13; 8:45 am]
BILLING CODE 3510-16-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.